Sugi Predict

Sugi Predict / Compounds / SCHEMBL1323923

SCHEMBL1323923

SCHEMBL1323923

O=C(Oc1ccccc1F)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.63
▸ MAPT P10636 3/20 0.63
▸ SMN1; SMN2 Q16637 2/20 0.63
▸ SLC6A3 Q01959 1/20 0.56
▸ ESR1 P03372 2/20 0.54
▸ ESR2 Q92731 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ JAK2 O60674 1/20 0.54
▸ USP2 O75604 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ SLC2A1 P11166 1/20 0.53
▸ SLC2A4 P14672 1/20 0.53
▸ SERPINE1 P05121 1/20 0.52
▸ LMNA P02545 2/20 0.50
▸ F2 P00734 1/20 0.50
▸ METAP2 P50579 1/20 0.50
▸ METAP1 P53582 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2838570 0.90 KMT2A (0.52) KMT2AMAPTSMN1; SMN2SLC6A3ESR1
SCHEMBL17951220 0.89 FAAH (0.52) KMT2AMAPTSMN1; SMN2SLC6A3ESR1
SCHEMBL10180669 0.87 KMT2A (0.58) KMT2AMAPTSMN1; SMN2SLC6A3ESR1
SCHEMBL2886267 0.85 SLC2A1 (0.72) KMT2AMAPTSMN1; SMN2SLC6A3ESR1
SCHEMBL10180883 0.85 KMT2A (0.56) KMT2AMAPTSMN1; SMN2SLC6A3ESR1
SCHEMBL10181125 0.85 KMT2A (0.56) KMT2AMAPTSMN1; SMN2SLC6A3ESR1
SCHEMBL10091157 0.85 ESR1 (0.56) KMT2AMAPTSMN1; SMN2SLC6A3ESR1
SCHEMBL725404 0.85 KMT2A (0.76) KMT2AMAPTSMN1; SMN2SLC6A3ESR1
SCHEMBL2838742 0.84 SLC2A1 (0.57) KMT2AMAPTSMN1; SMN2ESR1ESR2
Hydrochloric Acid SCHEMBL16050041 0.83 KMT2A (0.73) KMT2AMAPTSMN1; SMN2SLC6A3ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117623975-A Allyl-containing alpha-quaternary carbon secondary amine compound and oxazine compound synthesized by same and containing quaternary carbon center 扬州大学 2024-03-01 — — CN claimed
CN-117623975-A Allyl-containing alpha-quaternary carbon secondary amine compound and oxazine compound synthesized by same and containing quaternary carbon center 扬州大学 2024-03-01 — — CN disclosed
US-10280149-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-05-07 — — US disclosed
CN-109311860-A For treating or preventing the Xanthone derivative of hepatitis type B virus disease 豪夫迈·罗氏有限公司 2019-02-05 — — CN disclosed
US-20180022727-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-01-25 — — US disclosed
CN-105473548-A Amide derivatives as lysophosphatidic acid receptor antagonists TAKEDA PHARMACEUTICALS CO 2016-04-06 — — CN disclosed
CN-104112870-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same MITSUBISHI CHEM CORP 2014-10-22 — — CN disclosed
CN-103930396-A Aniline derivatives,their preparation and their therapeutic application FOVEA PHARMACEUTICALS 2014-07-16 — — CN disclosed
US-8609696-B2 Serotonin 5-HT2B receptor inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-12-17 — — US disclosed
US-20130244122-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME ONUKI MASAMICHI (JP) 2013-09-19 — — US disclosed
CN-1178932-C Amide derivatives — 2004-12-08 — — CN disclosed
CN-1170826-C Amide compound ����ҩƷ��ҵ��ʽ���� 2004-10-13 — — CN disclosed
CN-1478082-A Pyrimidine compound and application thereof ס�ѻ�ѧ��ҵ��ʽ���� 2004-02-25 — — CN disclosed
CN-1376153-A Amide compound FUJISAWA PHARMACEUTICAL CO (JP) 2002-10-23 — — CN disclosed
CN-1350530-A Amide derivatives ASTRAZENECA AB (SE) 2002-05-22 — — CN disclosed
CN-1080257-C Guanidine derivatives as inhibitors of Na+/H+ exchange in cells FUJISAWA PHARMACEUTICAL CO (JP) 2002-03-06 — — CN disclosed
CN-1123545-A Guanidine derivatives as inhibitors of Na+/H+ exchange in cells FUJISAWA PHARMACEUTICAL CO (JP) 1996-05-29 — — CN disclosed
EP-0357702-B1 FLUORINATED OLIGOPHENYL DERIVATIVES MERCK PATENT GmbH (DE) 1992-08-12 — — EP disclosed
EP-0357702-A1 FLUORINATED OLIGOPHENYL DERIVATIVES. MERCK PATENT GMBH (DE) 1990-03-14 — — EP disclosed
WO-1989006678-A1 FLUORINATED OLIGOPHENYL DERIVATIVES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1989-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280149-B2 Therapeutic compounds and uses thereof KDM1B, KDM6B, KDM2B KMT2A 29/4885MAPT 1631/4885SMN1; SMN2 660/4885
US-20180022727-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF KDM1B, KDM6B, KDM2B KMT2A 29/4885MAPT 1631/4885SMN1; SMN2 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.